Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?

Yiyuan Li, Shen Lin, Lixian Zhong, Shaohong Luo, Xiaoting Huang, Xiaojia Huang, Liangliang Dong, Xiongwei Xu, Xiuhua Weng

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To compare the cost-effectiveness of olaparib versus control treatment in metastatic castration-resistant prostate cancer patients with at least one gene mutation in BRCA1, BRCA2 or ATM from the US payer perspective. Methods: A Markov model was constructed to assess the quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios. Sensitivity analyses and scenario analyses were conducted to explore the impact of uncertainties. Results: The base-case result indicated that, for patients with specific gene mutations, olaparib gained 1.26 QALYs and USD$157,732 total cost. Compared with control treatment, the incremental cost-effectiveness ratio of olaparib was USD$248,248/QALY. The price of olaparib was the most influential parameter. Conclusion: Olaparib is not cost effective in comparison with control treatment in metastatic castration-resistant prostate cancer patients with specific gene mutations.

Original languageEnglish (US)
Pages (from-to)809-819
Number of pages11
JournalPharmacogenomics
Volume22
Issue number13
DOIs
StatePublished - Aug 2021

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint

Dive into the research topics of 'Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?'. Together they form a unique fingerprint.

Cite this